|Tested species reactivity||Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A 19 amino acid peptide near the carboxy terminus of human PION.|
|Purification||Antigen affinity chromatography|
|Contains||0.02% sodium azide|
|Storage Conditions||Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C|
|Tested Applications||Dilution *|
|Immunocytochemistry (ICC)||20 ug/ml|
|Immunofluorescence (IF)||20 µg/ml|
|Immunohistochemistry (IHC)||5 µg/ml|
|Western Blot (WB)||0.25 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
A suggested positive control is EL4 cell lysate.
PA5-21092 can be used with blocking peptide PEP-1206.
Accumulation of the amyloid-beta peptide (Abeta) in the cerebral cortex is a critical event in the pathogenesis of Alzheimer and quote;s disease. The beta-amyloid protein precursor (APP) is cleaved by one of two beta-secretases (BACE and BACE2), producing a soluble derivative of the protein and a membrane anchored 99 -amino acid carboxy-terminal fragment (C99). The C99 fragment serves as substrate for -gamma-secretase to generate the 4 kDa amyloid-beta peptide (Abeta), which is deposited in the Alzheimer and quote;s disease patients and quote; brains. PION, or GSAP, selectively increases amyloid-beta production through a mechanism involving its interaction with both -gamma-secretase and the APP C-terminal fragment, suggesting that PION may be a potential therapeutic target for the treatment of Alzheimer and quote;s disease.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.